Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

This article has a correction. Please see:

Correction: Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma - October 01, 2021

PDF +
Supplementary
Material

Immunotherapy biomarkers

Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma

Online download statistics by month:

Online download statistics by month: September 2021 to January 2023

	Abstract	Full	Pdf
Sep 2021	66	66	4
Oct 2021	836	838	223
Nov 2021	402	402	91
Dec 2021	274	287	63
Jan 2022	365	393	133
Feb 2022	274	286	91
Mar 2022	233	248	104
Apr 2022	278	285	65
May 2022	285	300	90
Jun 2022	257	281	89
Jul 2022	297	302	79
Aug 2022	290	301	114
Sep 2022	245	252	104
Oct 2022	407	410	94
Nov 2022	338	340	92
Dec 2022	198	203	63
Jan 2023	279	280	62
Total	5324	5474	1561